EGFR and non-small cell lung carcinoma: Inhibitors of EGFR tyrosine kinase used in clinical practice include gefitinib, erlotinib, and afatinib, which are used in therapy against non-small cell lung cancers (NSCLCs) harboring EGFR mutations16, 17, 18.